← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Sonnet BioTherapeutics Holdings, Inc. (SONN) 10-Year Financial Performance & Capital Metrics

SONN • • Industrial / General
HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology
AboutSonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.Show more
  • Revenue $1M +5268.8%
  • EBITDA -$16M -34.7%
  • Net Income -$16M -116.6%
  • EPS (Diluted) -3.95 +65.2%
  • Gross Margin -
  • EBITDA Margin -1584.41% +97.5%
  • Operating Margin -1584.41% +97.5%
  • Net Margin -1611.27% +96.0%
  • ROE -312.81%
  • ROIC -456.2%
  • Debt/Equity 0.00
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 0.5x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 4 (bottom 4%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-31.25%
5Y-
3Y41.91%
TTM1689.52%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-69.76%

EPS CAGR

10Y-
5Y-
3Y-
TTM66.07%

ROCE

10Y Avg-1139.46%
5Y Avg-266.62%
3Y Avg-306.21%
Latest-306.21%

Peer Comparison

Immuno-Oncology
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
IMTXImmatics N.V.1.33B9.9270.86188.6%-136.72%-27.81%0.03
CTMXCytomX Therapeutics, Inc.720.1M4.2511.1836.45%24.66%26.09%
IOVAIovance Biotherapeutics, Inc.881.27M2.22-1.73136.99%-158.78%-56.62%0.08
REPLReplimune Group, Inc.572.64M7.30-2.38-117.82%0.18
NKTRNektar Therapeutics719.28M35.36-4.079.22%-192.87%-141.9%1.69
IMNMImmunome, Inc.2.52B22.85-4.57-35.5%-23.01%-84.4%0.03
IBRXImmunityBio, Inc.3.89B3.95-6.3722.71%-422.28%
NRIXNurix Therapeutics, Inc.1.91B18.86-6.55-29.15%-292.5%-65.76%0.05

Profit & Loss

Dec 2016Dec 2017Dec 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Sales/Revenue+41.7M41.43M30.73M40.61M0483.63K349.94K147.81K18.63K1M
Revenue Growth %-0.02%-0.01%-0.26%0.32%-1%--0.28%-0.58%-0.87%52.69%
Cost of Goods Sold+38.38M39.41M29.94M7.93M58.31K093.26K000
COGS % of Revenue0.92%0.95%0.97%0.2%--0.27%---
Gross Profit+3.33M2.03M791.11K32.68M-58.31K483.63K-21.09M147.81K18.63K0
Gross Margin %0.08%0.05%0.03%0.8%-1%-60.28%1%1%-
Gross Profit Growth %-0.88%-0.39%-0.61%40.31%-1%9.29%-44.62%1.01%-0.87%-1%
Operating Expenses+5.95M4.55M3.86M4.71M17.41M25.57M8.58M18.94M11.87M16.84M
OpEx % of Revenue0.14%0.11%0.13%0.12%-52.87%24.5%128.14%637.18%16.84%
Selling, General & Admin5.95M4.55M3.86M2.51M7.53M8.94M8.58M7.13M6.13M8.49M
SG&A % of Revenue0.14%0.11%0.13%0.06%-18.48%24.5%48.21%329.16%8.49%
Research & Development00154.72K2.2M9.88M16.63M21.44M11.81M5.74M8.36M
R&D % of Revenue--0.01%0.05%-34.4%61.28%79.93%308.02%8.36%
Other Operating Expenses0011.05M000-21.44M000
Operating Income+-2.62M-2.52M-3.07M-4.71M-17.41M-25.09M-29.67M-18.79M-11.85M-15.84M
Operating Margin %-0.06%-0.06%-0.1%-0.12%--51.87%-84.78%-127.14%-636.18%-15.84%
Operating Income Growth %0.77%0.04%-0.22%-0.53%-2.7%-0.44%-0.18%0.37%0.37%-0.34%
EBITDA+-278.19K-237.68K-1.25M-1.16M-17.35M-24.99M-29.58M-18.72M-11.77M-15.84M
EBITDA Margin %-0.01%-0.01%-0.04%-0.03%--51.68%-84.52%-126.63%-631.72%-15.84%
EBITDA Growth %0.97%0.15%-4.28%0.07%-13.91%-0.44%-0.18%0.37%0.37%-0.35%
D&A (Non-Cash Add-back)2.34M2.28M1.82M3.54M58.31K95.16K93.26K75.75K83.11K0
EBIT-1.8M-5.22M-5.52M-16.7M-24.27M-25.09M-29.67M-18.79M-11.85M0
Net Interest Income+00-381.68K-162.87K0150000
Interest Income000020.68K150000
Interest Expense-2.35M-2.59M381.68K162.87K20.68K00000
Other Income/Expense-1.53M-5.29M-7.38M-162.87K-6.85M103.47K-52.48K-40.08K4.41M51.03K
Pretax Income+-4.15M-7.81M-8.07M-4.87M-24.27M-24.98M-29.72M-18.83M-7.44M-15.79M
Pretax Margin %-0.1%-0.19%-0.26%-0.12%--51.66%-84.93%-127.42%-399.29%-15.79%
Income Tax+198.46K-644.43K-701.22K162.87K00000-218.4K
Effective Tax Rate %2.19%0.87%0.85%1%1%1%1%1%1%1.02%
Net Income+-9.08M-6.79M-6.85M-4.87M-24.27M-25.01M-29.77M-18.83M-7.44M-16.11M
Net Margin %-0.22%-0.16%-0.22%-0.12%--51.71%-85.08%-127.42%-399.29%-16.11%
Net Income Growth %0.25%0.25%-0.01%0.29%-3.98%-0.03%-0.19%0.37%0.61%-1.17%
Net Income (Continuing)-4.35M-7.17M-7.37M-4.87M-24.27M-24.98M-29.72M-18.83M-7.44M0
Discontinued Operations-4.81M000000000
Minority Interest791.42K782.45K827.04K827.04K000000
EPS (Diluted)+-269068.00-175138.00-126904.00-163753.00-17159.00-2507.83-1203.05-145.12-11.35-3.95
EPS Growth %0.51%0.35%0.28%-0.29%0.9%0.85%0.52%0.88%0.92%0.65%
EPS (Basic)-269068.00-175138.00-126904.00-163753.00-17159.00-2507.83-1203.05-145.12-11.35-3.95
Diluted Shares Outstanding3439551093.82K9.96K24.7K129.77K655.24K4.08M
Basic Shares Outstanding3439551093.82K9.96K24.7K129.77K655.24K4.08M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Current Assets+1.79M1.8M1.34M39.75K7.64M28.81M5.41M4.74M2.12M14.34M
Cash & Short-Term Investments268.57K438.49K524.11K35.65K7.35M27.62M3.05M2.27M149.46K5.12M
Cash Only268.57K438.49K524.11K35.65K7.35M27.62M3.05M2.27M149.46K5.12M
Short-Term Investments0000000000
Accounts Receivable524.48K475.99K325.36K223.96K00717.3K786.57K762.08K0
Days Sales Outstanding4.594.193.862.01--748.171.94K14.93K-
Inventory539.55K460.76K335.21K354.34K000000
Days Inventory Outstanding5.134.274.0916.3------
Other Current Assets461.07K589.84K159.21K-578.3K00-717.3K1.68M09.22M
Total Non-Current Assets+31.69M28.38M28.45M28.12M356.77K182.27K416.08K691.25K653.09K541.83K
Property, Plant & Equipment11.51M8.55M9.76M10.47M273.81K182.27K302.81K227.06K143.94K54.68K
Fixed Asset Turnover3.62x4.85x3.15x3.88x-2.65x1.16x0.65x0.13x18.29x
Goodwill12.41M12.65M10.56M11.28M000000
Intangible Assets18.94M18.54M15.03M5.12M000000
Long-Term Investments800K800K800K800K000000
Other Non-Current Assets442.74K490.33K2.86M446.64K82.96K0113.28K464.19K509.15K487.15K
Total Assets+33.49M30.18M29.79M39.75K7.99M28.99M5.83M5.43M2.77M14.88M
Asset Turnover1.25x1.37x1.03x1021.63x-0.02x0.06x0.03x0.01x0.07x
Asset Growth %-0.21%-0.1%-0.01%-1%200.1%2.63%-0.8%-0.07%-0.49%4.37%
Total Current Liabilities+12.11M14.73M13.03M2.89M4.72M6.7M8.16M5.52M3.21M4.1M
Accounts Payable3.81M3.68M2.38M1.84M2.06M3.78M4.75M2.2M2.18M2.94M
Days Payables Outstanding36.2234.0729.0384.7912.88K-18.6K---
Short-Term Debt6.38M8.74M6.66M217.38K21.18K74874873.05K046.57K
Deferred Revenue (Current)173.78K83.88K1000K983.49K500K516.37K166.43K18.63K00
Other Current Liabilities1.67M2.4M3.97M-983.49K1.42M1.32M1.98M1.07M151.63K4.05M
Current Ratio0.15x0.12x0.10x0.01x1.62x4.30x0.66x0.86x0.66x3.50x
Quick Ratio0.10x0.09x0.08x-0.11x1.62x4.30x0.66x0.86x0.66x3.50x
Cash Conversion Cycle-26.5-25.61-21.08-66.48------
Total Non-Current Liabilities+7.41M3.96M8.51M17.71M250.01K30.61K203.91K130.86K46.57K0
Long-Term Debt3.97M852.38K3.67M15.91M124.88K00000
Capital Lease Obligations0-175K015.91M125.13K30.61K203.91K130.86K46.57K0
Deferred Tax Liabilities1.49M779.36K76.77K119.92K000000
Other Non-Current Liabilities1.96M2.16M3.58M0000000
Total Liabilities19.52M18.69M21.54M2.89M4.97M6.73M8.37M5.66M3.26M4.1M
Total Debt+10.35M9.59M10.34M217.38K353.25K125.88K255.99K203.91K130.86K46.57K
Net Debt10.08M9.16M9.81M181.73K-7M-27.5M-2.8M-2.07M-18.59K-5.07M
Debt / Equity0.76x0.84x1.25x-0.12x0.01x---0.00x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage---8.05x-28.91x-842.06x-----
Total Equity+13.61M11.49M8.26M-2.02M3.02M22.26M-2.54M-225.98K-485.74K10.79M
Equity Growth %-0.39%-0.16%-0.28%-1.24%2.5%6.37%-1.11%0.91%-1.15%23.21%
Book Value per Share401983.49291490.32150281.61-18528.84789.932234.48-102.76-1.74-0.742.64
Total Shareholders' Equity12.82M10.71M7.43M-2.85M3.02M22.26M-2.54M-225.98K-485.74K10.79M
Common Stock2.14K3053735551.47K6.03K55417565708
Retained Earnings-42.21M-49.11M-57.12M-12.44M-36.71M-61.69M-91.41M-110.24M-117.68M-133.69M
Treasury Stock-55.92M000000000
Accumulated OCI-1.16M-934.9K-202.12K0000000
Minority Interest791.42K782.45K827.04K827.04K000000

Cash Flow

Dec 2016Dec 2017Dec 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Cash from Operations+-509.16K-724.43K-1.11M-2.23M-15.61M-22.55M-27.69M-21.34M-8.61M-12.83M
Operating CF Margin %-0.01%-0.02%-0.04%-0.05%--46.63%-79.12%-144.39%-462.13%-12.83%
Operating CF Growth %0.91%-0.42%-0.53%-1.01%-6.02%-0.44%-0.23%0.23%0.6%-0.49%
Net Income-4.27M-6.79M-6.86M-5.03M-24.27M-24.98M-29.72M-18.83M-7.44M-16.01M
Depreciation & Amortization2.34M2.28M1.82M2.16M58.31K95.16K93.26K75.75K83.11K89.26K
Stock-Based Compensation000430K370.06K1.38M876.37K248.63K231.19K199.59K
Deferred Taxes131.78K-706.2K-779.36K-702.59K0-125.5K0000
Other Non-Cash Items4.71M6.66M3.03M-1.21M6.83M623971.48K282K384.16K2.9M
Working Capital Changes25.23K1.31M2.62M2.13M1.4M1.09M93.46K-3.12M-1.87M0
Change in Receivables-336.55K35.15K114.01K91.8K000-69.27K24.5K0
Change in Inventory33.22K23.06K72.8K8.88K000000
Change in Payables1.54M1.04M2.51M1.39M168.81K1.72M971.04K-2.63M48.42K630.38K
Cash from Investing+-430.82K-439.3K-1.25M-2.44M-76.18K-3.62K-896.48K-443.25K-12K-12K
Capital Expenditures-1.19M-1.63M-1.7M-2.39M-76.18K-3.62K-896.48K-443.25K-12K0
CapEx % of Revenue0.03%0.04%0.06%0.06%-0.01%2.56%3%0.64%-
Acquisitions----------
Investments----------
Other Investing0461.16K-322.28K-1.49M00000-12K
Cash from Financing+-21.98K1.36M1.32M2.26M23.01M42.83M4.01M21.01M6.49M26.05M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing00383.08K-526.06K3.81M008492.6M26.05M
Net Change in Cash----------
Free Cash Flow+-1.7M-2.35M-2.81M-4.62M-15.69M-22.56M-28.58M-21.79M-8.61M-12.83M
FCF Margin %-0.04%-0.06%-0.09%-0.11%--46.64%-81.68%-147.39%-462.13%-12.83%
FCF Growth %0.76%-0.38%-0.2%-0.64%-2.4%-0.44%-0.27%0.24%0.6%-0.49%
FCF per Share-50209.69-59620.31-51110.72-42397.26-4104.36-2264.19-1157.00-167.87-13.14-3.14
FCF Conversion (FCF/Net Income)0.06x0.11x0.16x0.46x0.64x0.90x0.93x1.13x1.16x0.80x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-50.76%-54.14%-69.42%-156.15%-4845.91%-197.83%-301.95%---312.81%
Return on Invested Capital (ROIC)-7.33%-8.53%-11.9%-43.5%------456.2%
Gross Margin7.98%4.89%2.57%80.47%-100%-6027.86%100%100%-
Net Margin-21.77%-16.4%-22.3%-11.99%--5170.52%-8508.34%-12741.58%-39929.3%-1611.27%
Debt / Equity0.76x0.84x1.25x-0.12x0.01x---0.00x
Interest Coverage---8.05x-28.91x-842.06x-----
FCF Conversion0.06x0.11x0.16x0.46x0.64x0.90x0.93x1.13x1.16x0.80x
Revenue Growth-1.64%-0.65%-25.82%32.15%-100%--27.64%-57.76%-87.4%5268.84%

Revenue by Segment

20122013201420152016
Better Burgers Fast Casual---14.54M22.59M
Better Burgers Fast Casual Growth----55.33%
Hooters Full Service---21.93M13.33M
Hooters Full Service Growth-----39.22%
Just Fresh Fast Casual---5.5M5.68M
Just Fresh Fast Casual Growth----3.38%
Corporate and Other---424.83K100K
Corporate and Other Growth-----76.46%

Revenue by Geography

20122013201420152016
United States---25.53M33.37M
United States Growth----30.74%
South Africa6.28M---5.41M
South Africa Growth-----
Europe-1.52M4.66M3.98M2.92M
Europe Growth--206.09%-14.43%-26.78%
AUSTRALIA--5.61M6.45M-
AUSTRALIA Growth---14.96%-
SOUTH AFRICA-5.74M6.63M6.43M-
SOUTH AFRICA Growth--15.56%-3.04%-
UNITED STATES-987.28K12.94M--
UNITED STATES Growth--1210.83%--
Hungary468.14K----
Hungary Growth-----

Frequently Asked Questions

Growth & Financials

Sonnet BioTherapeutics Holdings, Inc. (SONN) reported $1.0M in revenue for fiscal year 2025. This represents a 32% decrease from $1.5M in 2011.

Sonnet BioTherapeutics Holdings, Inc. (SONN) grew revenue by 5268.8% over the past year. This is strong growth.

Sonnet BioTherapeutics Holdings, Inc. (SONN) reported a net loss of $13.6M for fiscal year 2025.

Dividend & Returns

Sonnet BioTherapeutics Holdings, Inc. (SONN) has a return on equity (ROE) of -312.8%. Negative ROE indicates the company is unprofitable.

Sonnet BioTherapeutics Holdings, Inc. (SONN) had negative free cash flow of $10.3M in fiscal year 2025, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.